Synapse - Robert Motzer

Results (1252)

Germline variants identified in patients with early-onset renal cell carcinoma referred for germline genetic testing

Journal Article

Truong, H.; Sheikh, R.; Kotecha, R.; Kemel, Y.; Reisz, P. A.; Lenis, A. T.; Mehta, N. N.; Khurram, A.; Joseph, V.; Mandelker, D.; more...
European Urology Oncology (2021)

Fulltext@MSK | Save

Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial

Journal Article

Regan, M. M.; Jegede, O. A.; Mantia, C. M.; Powles, T.; Werner, L.; Motzer, R. J.; Tannir, N. M.; Lee, C. H.; Tomita, Y.; Voss, M. H.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial

Meeting Abstract

Apolo, A. B.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C. H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies

Meeting Abstract

Tannir, N. M.; Agarwal, N.; Porta, C.; Lawrence, N. J.; Motzer, R. J.; Lee, R. J.; Jain, R. K.; Davis, N. B.; Appleman, L. J.; Goodman, O. B.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms

Meeting Abstract

Grünwald, V.; Powles, T.; Kopyltsov, E.; Kozlov, V.; Gordoa, T. A.; Eto, M.; Hutson, T. E.; Motzer, R. J.; Winquist, E.; Maroto-Rey, P.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms

Meeting Abstract

Hutson, T. E.; Choueiri, T. K.; Motzer, R. J.; Rha, S. Y.; Alyasova, A.; Merchan, J. R.; Gurney, H.; Peer, A.; Takagi, T.; Porta, C.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)

Meeting Abstract

Motzer, R. J.; Porta, C.; Alekseev, B.; Rha, S. Y.; Choueiri, T. K.; Mendez-Vidal, M. J.; Hong, S. H.; Kapoor, A.; Goh, J. C.; Eto, M.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC)

Meeting Abstract

Shah, A. Y.; Motzer, R. J.; Apolo, A. B.; Powles, T.; Escudier, B.; Zhang, J.; Scheffold, C.; Karumanchi, S.; Nguyen, L. T.; Choueiri, T. K.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101

Meeting Abstract

Haanen, J. B. A. G.; Larkin, J.; Choueiri, T. K.; Albiges, L.; Rini, B. I.; Atkins, M. B.; Schmidinger, M.; Penkov, K.; Thomaidou, D.; Wang, J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; DiSimone, C.; Shaffer, D. R.; Sarrió, R. G.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save